Welcome to our dedicated page for Sotera Health news (Ticker: SHC), a resource for investors and traders seeking the latest updates and insights on Sotera Health stock.
Sotera Health Company provides sterilization solutions, lab testing and advisory services for the healthcare industry through Sterigenics, Nordion and Nelson Labs. News about SHC commonly covers quarterly and annual operating results, constant-currency revenue trends, Adjusted EBITDA commentary and outlook updates across those businesses.
Recurring company developments also include segment performance in outsourced terminal sterilization, irradiation services and laboratory testing, as well as governance changes, board committee assignments and capital-structure activity involving its Nasdaq-listed common stock. Sterigenics uses gamma irradiation, EO processing and E-beam irradiation for medical device, pharmaceutical, food safety and other application markets.
Sotera Health Company (Nasdaq: SHC) reported its Q2 2024 financial results, showing 8.3% growth in net revenues to $277 million. However, net income decreased to $9 million ($0.03 per diluted share) from $24 million ($0.08 per diluted share) in Q2 2023, primarily due to debt refinancing charges. Adjusted EBITDA increased by 6.9% to $137 million, while Adjusted EPS slightly declined to $0.19.
For the first half of 2024, net revenues increased by 10.3% to $525 million, with Adjusted EBITDA up 9.8% to $249 million. The company successfully refinanced its debt structure, extending maturities to 2031. Sotera Health reaffirmed its 2024 outlook, projecting 4-6% growth in net revenues and Adjusted EBITDA.
Sotera Health Company (Nasdaq: SHC) has appointed Christopher Simon as a new independent director to its Board of Directors. Simon will serve on the Leadership Development and Compensation Committee. He brings over 30 years of experience in business transformation and growth, currently serving as President and CEO of Haemonetics (NYSE: HAE). Simon's background includes roles at McKinsey & Company, Baxter Healthcare , and as a U.S. Army Infantry Officer.
Michael B. Petras, Jr., Chairman and CEO of Sotera Health, expressed excitement about Simon's addition, citing his leadership experience as a public company CEO and extensive commercial and strategic expertise in the life sciences industry as valuable assets for the company's growth. Simon also serves on the board of directors of AdvaMed, a global medical technology trade association.
Sotera Health Company (Nasdaq: SHC), a leading global provider of sterilization solutions and lab testing services for the healthcare industry, has announced its plans to release second-quarter 2024 financial results on Monday, August 5, 2024, before the market opens. The company will hold a conference call at 9:00 a.m. Eastern Time to discuss operating highlights and financial results.
To participate in the live call, investors can dial 1-844-481-2916 from the United States or 1-412-317-0709 from other locations. A live webcast of the conference call will be available on the company's website, along with accompanying materials. A replay of the webcast will be available later on the same day.
Sotera Health (Nasdaq: SHC) has announced the successful closing of a $1.51 billion Term Loan B and $750 million in senior secured notes, both maturing in 2031. The company will use the proceeds to refinance its existing $1.76 billion and $496.3 million Term Loan B facilities. This refinancing is expected to save approximately $5 million in interest expenses for 2024, reducing the projected interest expense to $165-175 million. Term Loan B offers a variable interest rate with options for SOFR-based or alternate base rate loans, and is prepayable without penalties after six months. The senior secured notes carry an interest rate of 7.375% per annum, payable semi-annually. This move is seen as favorable and reflects the market's confidence in Sotera Health's business strength.
Sotera Health reported positive financial results for the first quarter of 2024, with a 12.5% increase in net revenues to $248 million compared to the same period in 2023. Net income also saw a significant improvement, reaching $6 million or $0.02 per diluted share. Adjusted EBITDA increased by 13.7% to $112 million, and Adjusted EPS remained steady at $0.13. The company reaffirmed its 2024 outlook, anticipating continued growth and navigating market challenges.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.